Discovery cohort (n=53) No (%) | Confirmation cohort (n=126) No (%) | Validation cohort (n=158) No (%) | |
Age (years) | |||
≤60 | 31 (58) | 45 (35.7) | 45 (28.5) |
>60 | 22 (42) | 81 (64.3) | 113 (71.5) |
Gender | |||
Female | 21 (40) | 49 (38.9) | 53 (33.5) |
Male | 32 (60) | 77 (61.1) | 105 (66.5) |
BRAF mutational status | |||
Negative | 37 (70) | 77 (61.1) | 100 (63.3) |
Positive | 16 (30) | 46 (36.5) | 57 (36.1) |
Unknown | 0 (0) | 3 (2.4) | 1 (0.6) |
No of organs involved | |||
1 | 7 (13) | 15 (11.9) | 32 (20.3) |
2 | 15 (28) | 40 (31.7) | 35 (22.2) |
3 | 14 (26) | 26 (20.6) | 43 (27.2) |
4 | 7 (13) | 19 (15.1) | 34 (21.5) |
5 | 7 (13) | 14 (11.1) | 6 (3.8) |
6 | 2 (4) | 7 (5.6) | 7 (4.4) |
≥7 | 1 (2) | 5 (4.0) | 1 (0.6) |
AJCC M stage (AJCC 2009) | |||
M0 | 1 (2) | 3 (2.4) | 8 (5.1) |
M1a | 2 (4) | 4 (3.2) | 10 (6.3) |
M1b | 8 (15) | 20 (15.9) | 27 (17.1) |
M1c | 42 (79) | 99 (78.6) | 113 (71.5) |
Visceral metastasis | |||
No | 14 (26) | 42 (33.3) | 66 (41.8) |
Yes | 39 (74) | 84 (66.7) | 92 (58.2) |
CNS metastasis | |||
No | 38 (72) | 81 (64.3) | 126 (79.7) |
Yes | 15 (28) | 45 (35.7) | 32 (20.3) |
Liver metastasis | |||
No | 36 (68) | 91 (72.2) | 111 (70.3) |
Yes | 17 (32) | 35 (27.8) | 47 (29.7) |
Prior treatment regimens | |||
Anti-CTLA-4 | 36 (68) | 54 (42.9) | 51 (32.3) |
Anti-PD-1 | 0 (0) | 4 (3.2) | 11 (7.0) |
BRAFi±MEKi | 10 (19) | 34 (27.0) | 29 (18.4) |
MEKi | 3 (6) | 0 (0.0) | 4 (2.5) |
Chemotherapy | 9 (17) | 28 (22.2) | 15 (9.5) |
Radiotherapy | 29 (55) | 53 (42.1) | 40 (25.3) |
Adjuvant interferon | 17 (32) | 49 (38.9) | 31 (19.6) |
Other | 1 (2) | 1 (0.8) | 1 (0.6) |
Line of treatment | |||
First line | 12 (23) | 48 (38.1) | 87 (55.1) |
Second line | 24 (45) | 40 (31.7) | 39 (24.7) |
≥Third line | 17 (32) | 38 (30.2) | 32 (20.3) |
AJCC 2009 refers to the AJCC staging guideline for melanoma from 2009.
AJCC, American Joint Committee on Cancer; BRAFi, BRAF inhibitors; CNS, central nervous system; CNS, central nervous system; PD-1, programmed death receptor-1.